A definitive evaluation of the efficacy of the FLT3 inhibitor sorafenib in the treatment of ETP-ALL will likely be provided by ongoing clinical trials enrolling both R/R ALL and AML patients (i.e., NCT03132454, NCT01620216) (Figure 3). This evidence concerns the gene FLT3 and acute myeloid leukemia.